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Introduction: Clinical decision making in the setting of computed 
tomography (CT) screening could benefit from accessible biomark-
ers that help predict the level of lung cancer risk in high-risk indi-
viduals with indeterminate pulmonary nodules.
Methods: To identify candidate serum biomarkers, we measured 70 
cancer-related proteins by Luminex xMAP (Luminex Corporation) 
multiplexed immunoassays in a training set of sera from 56 patients 
with biopsy-proven primary non–small-cell lung cancer and 56 age-, 
sex-, and smoking-matched CT-screened controls.
Results: We identified a panel of 10 serum biomarkers—prolactin, 
transthyretin, thrombospondin-1, E-selectin, C-C motif chemokine 
5, macrophage migration inhibitory factor, plasminogen activa-
tor inhibitor, receptor tyrosine-protein kinase, erb-2, cytokera-
tin fragment 21.1, and serum amyloid A—that distinguished lung 
cancer patients from controls with an estimated balanced accuracy 
(average of sensitivity and specificity) of 76.0 ± 3.8% from 20-fold 
internal cross-validation. We then iteratively evaluated this model 
in an independent test and verification case/control studies confirm-
ing the initial classification performance of the panel. The classifi-
cation performance of the 10-biomarker panel was also analytically 
validated using enzyme-linked immunosorbent assays in a second 
independent case/control population, further validating the robust-
ness of the panel.
Conclusions: The performance of this 10-biomarker panel–based 
model was 77.1% sensitivity/76.2% specificity in cross-validation in 
the expanded training set, 73.3% sensitivity/93.3% specificity (bal-
anced accuracy 83.3%) in the blinded verification set with the best 
discriminative performance in stage I/II cases: 85% sensitivity (bal-
anced accuracy 89.2%). Importantly, the rate of misclassification of 
CT-screened controls was not different in most control subgroups 
with or without airflow obstruction or emphysema or pulmonary 
nodules. These biomarkers have potential to aid in the early detec-
tion of lung cancer and more accurate interpretation of indeterminate 
pulmonary nodules detected by CT screening.
Key Words: Lung cancer, Serum protein biomarkers, CT screening, 
Luminex xMAP immunoassays, Pulmonary nodules.
(J Thorac Oncol. 2012;7: 698–708)
Lung cancer is the leading cause of cancer deaths in the United States, with more than 190,000 deaths per year. 
Nearly 60% of patients diagnosed with lung cancer die within 
1 year of their diagnosis; nearly 75% die within 2 years with a 
5-year survival less than 16%. Poor survival is largely because 
of the late stage at which lung cancer is currently detected. 
The cost to the U.S. health care system caused by lung cancer 
is about $12 billion (in 2009 dollars) annually, representing 
2% of health care costs.1 Despite these statistics, lung cancer 
screening is not currently recommended.2 Early detection is 
complicated by the inaccessibility of the lungs and the con-
sequent risks involved in obtaining lung tissue for pathologi-
cal diagnosis. Chest radiographs and sputum cytology were 
previously examined for use in screening, but clinical trials 
using these low-sensitivity screening methods failed to show 
a benefit for overall survival. More sensitive computed tomog-
raphy (CT) imaging technology makes detection of early lung 
cancer feasible.3
Since the publication of the Early Lung Cancer Action 
study in 1999,4 CT screening for detecting lung cancer in clini-
cally asymptomatic, high-risk subjects (e.g., individuals aged 
>50 years with a substantial smoking history) has generated 
both interest and controversy, and there is continuing debate 
regarding the benefits and risks of lung cancer screening.5 
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Thoracic CT scans are much more sensitive than chest radio-
graphs but a common confounding observation is the detec-
tion of benign pulmonary nodules with a reported range of 
20 to 50% on initial screening of participants in single-arm 
CT screening trials.6 In our ongoing CT screening study, the 
Pittsburgh Lung Screening Study (PLuSS), 2.2% of the more 
than 3600 screened high-risk smokers were diagnosed with 
primary lung cancer in the first 3 years of the study; however, 
40.6% of the PLuSS participants had a noncalcified nodule 
detected by CT scan, and 821 of these subjects underwent addi-
tional CT and/or positron emission tomography scans.7 of all 
PLuSS subjects, 1% had a major invasive thoracic procedure 
such as thoracotomy or video-assisted thoroscopic surgery to 
remove what turned out to be a benign pulmonary nodule dur-
ing the first 3 years of follow-up.7 As in previously published 
CT screening studies, PLuSS did detect a large number of lung 
cancers at an early, curable stage (64 stage I, 7 stage II, 36 
stage III, and 12 stage IV) in the first 5 years but the screen-
ing also resulted in considerable medical risks and medical 
costs. An initial report from the National Lung Screening Trial 
(NLST) also documented a high rate of invasive procedures for 
CT-detected pulmonary nodules that were benign.8 This obser-
vation was confirmed and extended in the recent full NLST 
publication,9 that demonstrated, for the first time, a significant 
20.0% relative reduction in lung cancer mortality with low-dose 
CT screening, which was accompanied, however, with a com-
bined rate of positive low-dose CT screening tests of 24.2%. In 
subjects with a positive CT screening finding of a pulmonary 
nodule, 96.4% were false-positive results for lung cancer.9 The 
risk of death caused by complications as a result of a major 
thoracic procedure approaches 1%, indicating the great need to 
avoid unnecessary thoracic procedures. However, the relatively 
favorable survival associated with early, particularly very early 
(stage IA), lung cancer strongly motivates the need and search 
for effective early detection methods. A recent review reported 
that stage IA patients, with tumor size less than 10 mm, who 
underwent complete resection, experienced an 86% overall and 
100% cancer-specific 5-year survival.10
We hypothesized that the addition of biomarker analysis 
to CT screening results can improve discrimination between 
individuals with and without lung cancer. Sensitive and spe-
cific lung cancer biomarkers, measured in noninvasively col-
lected biospecimens such as serum, could help guide clinical 
decision making regarding the level of lung cancer risk in high-
risk subjects, particularly in patients with CT-detected indeter-
minate pulmonary nodules. Application of robust biomarkers 
could potentially reduce risks and costs of CT screening, while 
allowing for the detection of lung cancer more often at an early 
stage where cure is much more likely. A small number of indi-
vidual serum biomarkers have been reported in lung cancer; 
however, none has been demonstrated to provide clinical util-
ity, mainly because of the lack of sufficient sensitivity (SN) and 
specificity (SP). Published studies have demonstrated elevated 
serum levels of cytokeratin fragment (Cyfra) 21.1, carcino-
embryonic antigen (CEA), and tissue plasminogen activator 
in non–small-cell lung cancer (NSCLC). However, these indi-
vidual biomarkers were found to have poor SN and SP.11,12 In 
addition, most biomarkers achieve better SN in advanced stage 
disease compared to stage I lung cancer and thus their use for 
early diagnosis or screening has not had an impact on patient 
care. The current lack of robust lung cancer serum biomarkers 
drives current research efforts, including this reported study, 
to identify and validate new biomarkers with potential clinical 
utility. Toward this end, we used serum samples collected from 
PLuSS cancer-free subjects, matched to serum from lung can-
cer cases of adenocarcinoma or squamous cell histology based 
on age, sex, and smoking status, to evaluate 70 cancer-associ-
ated protein biomarkers representing a spectrum of biological 
functions selected on the basis of published studies document-
ing an association with epithelial cancer development and pro-
gression in a training set and evaluated the performance of the 
resulting 10-biomarker panel in independent test and verifica-
tion case/control sample sets including subjects with a clinical 
spectrum of potentially confounding nonmalignant lung dis-
ease including airflow obstruction, emphysema, or pulmonary 
nodules.
PATIENTS AND METHODS
Lung Cancer Cases
Patients with clinically ascertained and biopsy-proven 
untreated primary lung cancer were consented to the University 
of Pittsburgh Cancer Institute (UPCI) Lung Research Registry, 
a University of Pittsburgh Institutional Review Board-approved 
clinical research protocol in the UPCI Specialized Program of 
Research Excellence (SPoRE) in Lung Cancer, and provided 
demographic data, including sex, age at diagnosis, and smok-
ing status, clinical information including histology and stage 
of tumor, and results of presurgical pulmonary function tests 
(PFTs), and blood collections for research. Blood samples 
were collected within 4 weeks of the first biopsy-proven lung 
cancer diagnosis and before removal of the cancer by a sur-
gical procedure. All cases used in this study were confirmed 
to be primary lung cancer by pathology review. Cancer cases 
were classified by PFTs for evidence of airflow obstruction. 
Using a standardized phlebotomy procedure, a 50-ml nonfast-
ing peripheral blood sample was collected without anticoagu-
lant from each consented patient to yield serum following a 
rigorous validated protocol based on prior recommendations 
from the National Institutes of Health and the National Cancer 
Institute Early Detection Research Network. Processing and 
final cryopreservation at –80°C were completed within 1 hour 
of blood collection. Serum aliquots used in the study were not 
thawed before the study assays.
Controls—The Pittsburgh Lung  
Screening Study
PLuSS is a community-based Institutional Review 
Board-approved study of lung cancer screening with low-dose 
multidetector helical CT, funded by the Lung Cancer SPoRE.7 
Beginning in early 2002, we recruited and screened 3642 vol-
unteers primarily from southwestern PA at high risk for lung 
cancer. The PLuSS participants also underwent spirometry 
for PFT because of the known relationship between chronic 
obstructive pulmonary disease (CoPD) and lung cancer.13 
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Airflow obstruction was classified by standard GoLD crite-
ria. All chest CT scans were obtained on multidetector helical 
CT scanners during a single breath-hold at full inspiration.7,13 
Three physician readers, a pulmonologist, a general radiolo-
gist, and a chest radiologist visually scored the baseline CT 
scans for the presence and type of pulmonary nodules and 
radiographic emphysema presence and severity. PLuSS sub-
jects were classified as having no nodule, a benign nodule (≤3 
mm), a low suspicion (4–7 mm), or a moderate/high suspicion 
nodule (8–20 mm). Patients with low-suspicion nodules or 
worse were followed for at least 3 years and all PLuSS sub-
jects with nodules used in this study had benign outcomes. 
Scoring procedures for emphysema used a five-level semi-
quantitative scale, based on National Emphysema Treatment 
Trial criteria, to represent no, trace, mild, moderate, and 
severe emphysema. We have demonstrated that radiographic 
emphysema is an important, independent risk factor for lung 
cancer within the PLuSS cohort.13 Peripheral blood was col-
lected from PLuSS subjects within 2 weeks of the baseline CT 
scan and processed and stored under the same rigorous condi-
tions described above.
Lung Cancer Case/Control Training,  
Testing, and Verification Sets
For our initial discovery study, sera from 56 NSCLC lung 
cancer patients were individually matched to a serum sample 
from 56 PLuSS participants who were known to be cancer-
free a minimum of 3 years following the baseline CT scan. 
Matching was based on age at serum collection (±5 years), 
sex, and smoking status (current or ex-smoker). A nested con-
current test set constituted 10 additional clinically ascertained 
and confirmed primary lung cancer cases, and 83 randomly 
selected, unmatched PLuSS subjects known to be cancer-free 
after a minimum of 3-year follow-up. The samples comprising 
the training and testing sets were run together in a single labo-
ratory run. An initial blinded verification set consisted of an 
independent randomly selected set of 30 primary lung cancer 
cases with a range of histologies and 30 unmatched PLuSS 
controls. These controls were also known to be cancer-free 
after a minimum 3-year follow-up. The samples in the verifica-
tion set were run blinded as an independent laboratory analysis 
subsequent to the training and testing set samples. The clinical 
and demographic characteristics of the cases and control sub-
jects comprising these sets are summarized in Table 1.
Luminex Multianalyte Profiling (xMAP)
Multiplexed serum immunoassays were performed 
using the Luminex Corporation xMAP technology platform 
(Luminex Corporation, Austin, TX) that facilitates the simul-
taneous quantitation of up to 100 soluble analytes in a single 
sample. A total of 70 cancer-associated candidate serum bio-
markers (Table 2) were analyzed in samples from lung can-
cer patients and matched controls. Together, these biomarkers 
incorporate a wide range of host and tumor-derived factors 
that allow a broad analysis of the lung cancer/host interac-
tion, and include a number of previously described epithelial 
cell cancer-associated serological markers. Although some of 
these biomarkers have been previously analyzed in lung can-
cer, no integrated analysis of the performance of these com-
bined biomarkers has been previously performed. The initial 
goal of this discovery study was to identify the most robust 
subset of these biomarkers to discriminate lung cancer and 
matched control samples.
TABLE 1. Clinical and Demographic Characteristics of the 
Primary Lung Cancer Cases and PLuSS Control Subjects Used 
in the Initial Training, Test, and Verification Sets
Characteristic Training Set Test Set Verification Set
Primary lung cancer cases n = 56 n = 10 n = 30
 Age (yr)
  38–44 0 0 3
  46–49 2 1 0
  50–59 6 2 3
  60–69 21 3 8
  70–79 22 3 10
  80+ 5 1 6
 Sex
  Male 30 4 13
  Female 26 6 17
 Smoking
  Never 0 0 1
  Previous 43 2 17
  Current 13 8 12
 Histology
  Adenocarcinoma 28 5 10
  Squamous cell 28 4 7
  Neuroendocrine 0 1 0
  Pleomorphic 0 0 2
  NSCLC, undifferentiated 0 0 8
  Small cell 0 0 3
 Stage
  IA/IB/limiteda 29 6 17
  IIA/IIB 7 2 3
  IIIA/IIB/extensivea 16 2 9
  IV 4 0 1
PLuSS control subjects n = 56 n = 83 n = 30
 Age (yr)
  38–44 0 0 0
  46–49 0 0 0
  50–59 10 34 19
  60–69 21 32 9
  70–79 25 17 2
  80+ 0 0 0
 Sex
  Male 30 50 12
  Female 26 33 18
 Smoking
  Never 0 0 0
  Previous 43 51 13
  Current 13 32 17
aLimited (n = 2) and extensive (n = 1) staging refer to small cell carcinoma only. 
PluSS, Pittsburgh Lung Screening Study; NSCLC, non–small-cell lung cancer.
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For these analytes, we used commercially available 
bead-based immunoassays together with custom research 
assays in xMAP format developed and validated in the 
Luminex Platform Laboratory (LPL) of the UPCI (http://
www.upci.upmc.edu/luminex/). Generation, optimization, 
and multiplexing of these bead-based serum protein immu-
noassays were performed as previously described.14,15 All 
assays were research grade. Multiplexed analyses were 
performed according to the manufacturers’ protocols as 
previously described.16 Samples were analyzed using the 
Bio-Plex suspension array system (Bio-Rad Laboratories, 
Hercules, CA). For each analyte, 100 labeled beads were 
analyzed for each sample and mean fluorescence intensities 
were calculated using the system software. Analysis of the 
experimental data and extrapolation to the standard curves 
was performed using four-parameter logistic curve fitting 
to derive the analyte concentrations in each sample. The 
intraassay variability of each assay was 1.5 to –6%. The 
interassay variability for assays performed on the same day 
was 3 to 9%; for assays performed on different days the 
interassay variability was 5 to 20% depending on whether 
the same lots of reagents were used.17–19 Each bead-based 
assay was previously validated in the UPCI LPL against the 
corresponding dedicated enzyme-linked immunosorbent 
assay (ELISA) using the same capture and detection anti-
body pairs with 89 to 98% correlation for the LPL assays. 
The performance of the purchased assays (Table 2) was in 
agreement with that claimed by the manufacturer.
Enzyme-Linked Immunosorbent Assays
ELISA kits for human thrombospondin-1, plasminogen 
activator inhibitor (PAI-1 and SERPINE1), and macrophage 
migration inhibitory factor (MIF), were purchased from R&D 
Systems (Minneapolis, MN). ELISA kits for CEA, receptor 
tyrosine-protein kinase (erb-2), and transthyretin (TTR) 
were purchased from Immunology Consultants Laboratory, 
Inc. (Minneapolis, MN), Calbiochem (Gibbstown, NJ), and 
ALPCo (Salem, NH), respectively. The assays were per-
formed according to protocols provided by the manufactur-
ers. Both standard samples containing recombinant proteins 
and the selected serum samples were assayed in duplicate to 
reduce variation.
Data Analysis, Biomarker Panel, and Model 
Development Approaches
our main approach for the initial data analysis was to 
apply feature selection and model development methods we 
had previously used for biomarker discovery to search for can-
didate multianalyte panels with estimated classification per-
formance above 80% SN and SP over cross-validation on the 
training data set. This was used to determine parameter set-
tings that would yield robust models likely to generalize to the 
test and verification set data. We then developed a model from 
the combined data using these parameter settings, and applied 
it to the independent verification set to evaluate its classifi-
cation performance. There are three main components in our 
rule learning approach: (1) efficient Bayesian discretization, 
TABLE 2. Candidate Luminex xMAP Lung Cancer Serum Biomarkers (n = 70)
Biological Group Protein Analytes Assay Source
Cytokines IL-6, IL-8, TNFa, TNF-RI, TNF-RII, G-CSF
G-CSF-R, M-CSF, IL-2R, IL-6R, IL-1RT1
sCD40-L, GRoa
Invitrogen/Biosource, Camarillo, CA
Bio-Rad Laboratories, Hercules, CA
Chemokines CCL5 (RANTES), MCP-1,3; eotaxin, LIF, MIF, IP-10 Invitrogen/Biosource
Bio-Rad Laboratories
Growth/angiogenic factors EGF, VEGF, bFGF, EGFR, c-ErbB-2, IGFBP-1, angiostatin,  
THBS1, HGF, NGF, PDGF, SCGF-β, SDF-1a, SCF
Invitrogen/Biosource
Bio-Rad Laboratories
UPCI LPL
Cancer antigens CEA, AFP, CA 72-4, TTR, HE4, SCC UPCI LPL
Apoptotic proteins Cyfra 21.1, TRAIL, sDR5, sFas, sFasL UPCI LPL
Proteases Kallikrein 10, MMP-1,7,8,9,12 UPCI LPL
R&D Systems, Minneapolis, MN
Adhesion molecules sICAM-1, sVCAM-1, E-selectin Millipore/Linco, St. Louis, Mo
Hormones PRL, TSH, LH, ACTH, GH, FSH Millipore/Linco
Adipokines Adiponectin, leptin, resistin Millipore/Linco
other biomarkers Mesothelin, Hsp70, ULBP-1,2, MICA, SAA
PAI-1 (SERPINE1), MPo, thrombospondin-1,
ULBP-1,2
UPCI LPL
Millipore/Linco
TNF, tumor necrosis factor; IL, interleukin; G-CSF, granulocyte colony-stimulating factor; M-CSF, macrophage colony stimulating factor; GRoa, growth-related oncogene a; 
CCL5, C-C motif chemokine 5; MCP, monocyte chemotactic protein; LIF, leukemia inhibitory factor; MIF, macrophage migration inhibitory factor; IP-10, interferon gamma-induced 
protein 10; IGFBP, insulin-like growth factor binding protein; PRL, prolactin; TSH, thyroid-stimulating hormone; THBS1, thrombospondin 1; NGF, nerve growth factor; PDGF, 
platelet-derived growth factor; SCGF, stem cell growth factor; SDF, stromal cell-derived factor; SCF, stem cell factor; CEA, carcinoembryonic antigen; AFP, a-fetoprotein; CA, 
carcinoembryonic antigen; TTR, transthyretin; SCC, squamous cell carcinoma; TRAIL, TNF-related apoptosis-inducing ligand; MMP, matrix metalloproteinases; LH, luteinizing 
hormone; ACTH, adrenocorticotropic hormone; GH, growth hormone; FSH, follicle-stimulating hormone; Hsp, heat shock protein; ULBP, UL16-binding proteins; SAA, serum 
amyloid A protein; PAI, plasminogen activator inhibitor; MPo, myeloperoxidase; EGF, endothelial growth factor; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast 
growth factor; EGFR, endothelial growth factor receptor; UPCI LPL, University of Pittsburgh Cancer Institute Luminex Platform Laboratory.
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(2) rule learner (RL) and (3) inference engine. Feature selec-
tion is automatically performed through the use of univariate 
Bayesian discretization by the rule learning toolkit that we 
used for modeling the immunoassay data. We have previously 
successfully applied and used this rule learning algorithm20–23 
to biomarker discovery from proteomic mass spectra obtained 
from cerebrospinal fluid for screening of amyotrophic lateral 
sclerosis24,25 and in a verification study of biomarkers for amy-
otrophic lateral sclerosis.26 A full description of our RL-based 
data analysis and prediction model development methods is 
included in Supplemental Material (Supplemental Digital 
Content 1, http://links.lww.com/JTo/A237).
RESULTS
Selected Biomarkers and Rule Models
Using our methods, we first derived a rule model from 
the initial training set comprising 11 rules that included 8 
biomarkers—prolactin, TTR, thrombospondin-1, E-selectin, 
C-C motif chemokine 5 (CCL5, RANTES), macrophage MIF, 
plasminogen activator inhibitor 1 (PAI-1 and SERPINE1), and 
receptor tyrosine-protein kinase erbB-2 (Table 3). This rule 
model distinguished the lung cancer case samples from the 
control samples in the training set with SN of 92.9% and SP 
of 87.5%. The balanced accuracy (BACC) from 20-fold inter-
nal cross-validation of the training set was 82.5 ± 4.8%. The 
rule model was then applied to the nested concurrent test set 
samples, achieving 90.0% SN and 77.1% SP (BACC 83.6%).
Further Training Led to a 10-Biomarker Model
We then used RL to learn a model using all the data for 
the combined training and test sets (205 subjects, 66 with lung 
cancer and 139 controls) to determine whether a more informa-
tive model could be found using all of the data in this larger set 
of cases and controls. In this expanded training set, the original 
eight proteins together with two additional biomarkers (cytok-
eratin fragment 19-9 [Cyfra 21.1] and serum amyloid A pro-
tein provided improved discriminative performance [Table 3]). 
Both of these proteins have been previously described as lung 
cancer serum biomarkers.11,12,32 The results from using posi-
tive predictive value as the certainty factor on this combined 
training set were 77.1% SN and 76.2% SP over 20-fold cross-
validation (BACC 76.0 ± 3.8%). This analysis yielded a final 
model consisting of a set of 12 rules with the 10 biomarkers. 
The 10-biomarker rule model is included as Supplementary 
Figure S2 (Supplemental Digital Content 2, http://links.lww.
com/JTo/A237). The classification performance of the indi-
vidual selected biomarkers in both the training and test sam-
ple sets is detailed in the Supplementary Table (Supplemental 
Digital Content 3, http://links.lww.com/JTo/A237).
Verification Set
A set of 60 independent serum samples, comprising 30 
randomly selected clinical lung cancer cases and 30 PLuSS 
controls, was processed and analyzed on the multiplex plat-
form as a blinded verification data set. The verification set 
samples were analyzed as a subsequent laboratory analysis 
to the initial run of the training and testing set samples. The 
clinical and demographic characteristics of these lung can-
cer cases and PLuSS control subjects comprising the verifi-
cation set are summarized in Table 1. Because all types of 
lung cancer have been detected in the PLuSS cohort by CT 
screening, the verification set included a range of lung can-
cer histologies including small cell carcinoma not included 
in the training and test samples. The previously identified 
10-biomarker panel analytes were measured as described. 
The previously collected data were calibrated together with 
the new data generated in the blinded verification set using 
the same procedure as described previously. This calibration 
procedure relies on the inclusion of quality control samples 
in each experimental plate in addition to the required con-
centration standards.
Applying the 10-biomarker panel and associated RL 
rules to the verification set data yields an overall classifi-
cation performance of 73.3% SN and 93.3% SP with only 
10 misclassifications among the 60 total predictions made 
TABLE 3. Candidate Luminex xMAP Lung Cancer Serum 10-Biomarker Panel
Protein Biomarker Gene Function Literaturea
Upregulated in lung cancer sera
 Cyfra 21.1 (Cytokeratin-19) [P08727] KRT19 Apoptosis ↑ [27]
 Macrophage migration inhibitory factor (MIF) [P14174] MIF Lymphokine ↑ [15,28,29]
 Prolactin (PRL) [P01236] PRL Hormone ↑ [30,31]
 Serum amyloid A Protein (SAA) [P02735] SAA1 Acute phase reactant ↑ [32]
Downregulated in lung cancer sera
 C-C motif chemokine 5 (CCL5, RANTES) [P13501] CCL5 Chemokine —
 E-selectin [P16581] SELE Cell adhesion ↑ [33–36]
 Receptor tyrosine-protein kinase erbB-2 [P04626] ERBB2 Growth factor ↑—[37–40]
 Serpine 1 (PAI-1) [P05121] SERPINE1 Protease inhibitor —
 Thrombospondin-1 [P07996] THBS1 Cell adhesion ↓ [41]
 Transthyretin (TTR) [P02766] TTR Protein transporter ↓ [42]
aSerum biomarker lung cancer case-control associations reported in the literature, — literature not informative, ↑ biomarker elevated in cases, ↓ biomarker depressed in cases, 
↑- biomarker elevated in cases according to some studies and unassociated with lung cancer according to other studies.
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(Tables 4 and 5), and may provide clinical utility in guiding 
interpretation of screening CT scans, even in tobacco-ex-
posed persons with CoPD or emphysema. Formal valida-
tion in larger patient cohorts will be needed to confirm these 
initial findings.
Analytical Validation of the 10-Biomarker  
Panel Using ELISAs
As a final evaluation of the candidate 10-biomarker 
panel, we performed individual ELISA measurements using 
commercially available kits to determine the level of these 
biomarkers in serum in a second independent set of 38 lung 
cancer cases and 76 controls representative of the previous 
case/control populations. We also included several biomark-
ers, specifically C-reactive protein (CRP), hepatocyte growth 
factor (HGF), and CEA, for individual ELISA measurement 
that had been reported in the literature to be differentially 
abundant in the serum of lung cancer patients, and which had 
been previously included in our initial Luminex discovery 
analysis. Using the serum level of each of the 10-biomarker 
panel proteins as determined by ELISA, the Naïve Bayes 
classification analysis with 10-fold cross-validation was able 
to discriminate cases from controls in this new set of subjects 
with an average accuracy of 78.95% (average SN 55.3% and 
average SP 90.8%), consistent with our previous verification 
findings, thus confirming the classification performance of 
the panel using an independent platform analysis. Addition 
of the ELISA data for HGF, CRP, and CEA to the analysis 
did not improve classification performance as these three 
biomarkers were found to highly correlated with others in 
our 10-biomarker panel. We conclude that the 10-biomarker 
panel has robust classification performance and can be used 
as the basis for further refinement, e.g., including novel bio-
markers not assayed to date, to produce an optimized serum-
based biomarker panel for detection of lung cancer.
TABLE 4. Misclassification of Lung Cancer Cases in the 
Verification Set
 
Characteristic
Verification Set
10-Biomarker Model
Total 8/30 (26.7%)
Sex
 Male 3/13 (23.1%)
 Female 5/17 (29.4%)
Age (yr)
 38–44 2/3 (66.7%)
 46–49 ND
 50–59 1/3 (33.3%)
 60–69 1/8 (12.5%)
 70–79 3/10 (30%)
 80+ 1/6 (16.7%)
Histology
 Adenocarcinoma 4/10 (40%)
 Squamous Cell 2/7 (28.6%)
 Neuroendocrine ND
 Pleomorphic 1/2 (50%)
 NSCLC, undifferentiated 1/8 (12.5%)
 Small cell 0/3 (0%)
Stage
 IA/IB/limiteda 3/17 (17.6%)
 IIA/IIB 0/3 (0%)
 IIIA/IIB/extensivea 5/9 (55.6%)
 IV 0/1 (0%)
Smoking status
 Never 0/1 (0%)
 Previous 5/17 (29.4%)
 Current 3/12 (25%)
Airflow obstruction
 Yes 5/18 (27.8%)
 No 2/5 (40%)
 Unknown 1/7 (14.3%)
aLimited (n = 2) and extensive (n = 1) stage refer to staging of small cell carcinomas 
only. ND, not done.
TABLE 5. Misclassification of PLuSS Controls in the 
Verification Set According to Demographic and Pulmonary 
Function Variables and Nodule Status
 
Lung Cancer Risk Factor
Verification Set
10-Biomarker Model
Total 2/30 (6.7%)
Sex
 Male 1/12 (9.1%)
 Female 1/18 (5.6%)
Age (yr)
 50–59 1/19 (5.3%)
 60–69 1/9 (11.1%)
 70–79 0/2 (0%)
Smoking status
 Previous 0/13 (0%)
 Current 2/17 (11.8%)
Emphysema
 None 0/21 (0%)*
 Trace 2/6 (33.3%)
 Mild 0/3 (0%)
 Moderate/severe ND
Airflow obstruction
 GoLD 0 (FVC > 80%) 1/11 (9.1%)
 GoLD 0 (FVC < 80%) 1/4 (25%)
 GoLD I 0/4 (0%)
 GoLD II 0/6 (0%)
 GoLD III 0/5 (0%)
 GoLD IV ND
Combined
 None/mild and GoLD 0–I 2/19 (10.6%)
 Moderate/severe and GoLD II–IV ND
 All others 0/11 (0%)
CT screening result
 No nodule or benign 2/15 (13.3%)
 Low suspicion nodule 0/15 (0%)
 Moderate/high suspicion nodule ND
*p = 0.04 (Fisher’s exact test)
ND, not done; CT, computed tomography.
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Impact of Demographic and Clinical Variables 
on Misclassifications by the Model
An important feature of the RL approach is that it assigns 
individual classifications to each case or control subject, allow-
ing for examination of possible confounders. The observed 
misclassification rates of the lung cancer cases and PLuSS 
controls in the model stratified by demographic and clinical 
variables are summarized in Tables 4 and 5. overall rates of 
misclassification by the 10-biomarker panel were 26.7% of 
cases and 6.7% of controls (Tables 4 and 5). The 10-biomarker 
panel yields equal performance in correctly distinguishing men 
and women as cases or controls, and smoking status was also 
not a factor in classification. Age overall was not a significant 
factor in the misclassification of cases or controls, although 
two of three cases aged 38 to 44 years were misclassified as 
controls by the 10-biomarker model. This inaccuracy may 
result from the absence of younger subjects in the training 
set that included no cases younger than 46 years at diagnosis 
and no controls younger than 50 years. Against all adenocar-
cinomas and squamous cell carcinomas in the verification set, 
the only two histologies of lung cancer in the training set, the 
10-biomarker model performed at an overall misclassification 
rate of 35.3% (BACC 63.8%, Tables 4 and 5). It appeared that 
the model tended to misclassify adenocarcinomas to a greater 
degree than squamous cell carcinomas (Table 4) although this 
difference was not statistically significant. The overall BACC 
in the verification set for all histologic types of lung cancer 
examined was 83.3% (SP 93.3%) for the 10-biomarker panel 
and, although the sample size was small, the model correctly 
classified all three small cell carcinomas (Table 4).
Among stage I/II lung tumors, the 10-biomarker panel mis-
classified 15% of stage I/II tumors in the verification set, com-
pared to 50% of the stage III/IV tumors (Table 4), suggesting the 
model performs well in discriminating early-stage lung cancer 
which was the predominant case group in the training and testing 
sets. With an SP of 93.3%, the 10-biomarker model BACC was 
89.2% in stage I/II disease. Application of Fisher’s exact test to 
these results reveals that none of the observed differences by sex, 
age, histology, stage, or smoking status are statistically significant 
given the relatively small sample sizes in each subgroup.
Examination of Classification Confounding  
by Airway Disease
Inflammatory response and immune cell functions 
were identified in the pathway analyses for the 10-biomarker 
panel (see below) and are known to contribute to CoPD. As 
CoPD is a known risk factor for lung cancer, it could be a 
confounding clinical variable in classification by the panel 
although airflow obstruction was not a factor in misclassifica-
tion in the 10-biomarker model (Tables 4 and 5). PFT results 
and measurements of radiographic emphysema were available 
for all the PLuSS controls (Table 5). Misclassification rates 
in these PLuSS controls showed no significant association 
with presence or degree of airflow obstruction in the model. 
The model had a higher misclassification rate in subjects with 
trace emphysema compared to no or mild emphysema (three-
class comparison, p = 0.04, Fisher’s exact test). Those controls 
with the best overall lung health (none to mild radiographic 
emphysema and scores of 0 or 1) did not show a significantly 
different misclassification rate than others (Table 5). In the 
model, the only misclassifications of controls were in subjects 
with no or minimal airway disease, suggesting that the pres-
ence of CoPD does not significantly contribute to incorrect 
predictions of controls as cases. Importantly, the presence or 
type of pulmonary nodules detected by CT screening also did 
not appear to contribute to misclassifications. In fact, those 
PLuSS subjects with a suspicious nodule were more often 
correctly classified as controls than those with no nodule or a 
benign nodule (Table 5). All nodules found in these subjects 
remained clinically noncancerous at least 3 years after initial 
detection, based on either resolution or no further growth on 
subsequent CT scans.
Lastly, we examined the model predictions in the veri-
fication set of the subset of clinical lung cancer cases whose 
invasive diagnostic procedures were triggered by CT pulmo-
nary nodule findings that were less than 3.5 cm in diameter. 
This type of patient is most comparable to those who might 
undergo routine CT screening with a resulting indeterminate 
pulmonary nodule. Twenty of the 30 cases fell in this category 
(Table 6). These patients were referred for CT for a number of 
clinical indications, including incidental findings because of 
workup for a nonpulmonary condition or pulmonary symp-
toms. Four of the 20 subjects with small CT nodules were 
being followed as the result of participation in PLuSS, so 
are among the CT-screened population. All the 20 patients 
received prompt invasive diagnostic procedures after a wor-
risome CT finding, at which time their blood was drawn for 
this study. The 10-biomarker panel predicted cancer correctly 
in 15 of 20 cases (75.0%), including 3 of the 4 PLuSS partici-
pants. of the remaining 10 subjects in the verification set with 
larger CT masses (>3.5 cm), the model correctly predicted 
cancer in 7 (Table 6). For CT findings of <2.0 cm, the model 
correctly predicted 5 of 8 (62.5%). These findings suggest that 
the model has robust predictive performance in patients with 
small tumors that would be detected by CT screening, and in 
CT-screened subjects without cancer.
Pathways Identified in the 10-Biomarker Model
Ingenuity Pathway Analysis software version 8.6 was 
used to determine cellular functions and diseases that might be 
associated with the informative biomarkers. All 10 biomarkers 
were eligible for pathway analysis by this software. A network 
was found encompassing all of the biomarkers, excluding 
TTR that was assigned to a separate network. The top diseases 
encompassed by the 10-biomarker panel were cancer, genetic 
disorder, metabolic disease, and inflammatory response. The top 
cellular functions identified were cell movement, cell signaling, 
and cell death. The top physiological functions identified were 
hematological system development, immune cell trafficking, 
tumor morphology, and tissue development. other molecules 
that were linked in a network with the biomarker panel included 
endothelial growth factor receptor, caspase, focal adhesion 
kinase, interleukin (IL)-1, IL-12, nuclear factor kB, trans-
forming growth factor , and the Fox family of transcription 
factors. In summary, these 10 proteins interconnect five major 
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functions, including two functions related to tumor biology 
(cancer and tumor morphology) and three functions related to 
the host response (inflammatory response, cell movement, and 
immune cell trafficking).
DISCUSSION
Although many individual serum biomarkers, or com-
binations of biomarkers, which have been reported to distin-
guish cancer patients from individuals without cancer have 
been reported, few are in clinical use. The major limitation has 
been lack of sufficient sensitivity (presence of false negatives) 
or specificity (presence of false positives). In addition to the 
previously referenced individual serum biomarkers Cyfra 21.1, 
CEA, and tissue plasminogen activator, the published literature 
contains a number of reports of the evaluation of panels of serum 
protein biomarkers associated with NSCLC. Khan et al43 had 
previously reported two of the serum biomarkers in our panel, 
serum amyloid A protein and MIF, as NSCLC serum biomark-
ers. Patz et al44 identified a four-serum protein panel compris-
ing CEA, retinol-binding protein, 1-antitrypsin, and squamous 
cell carcinoma antigen, which together correctly classified lung 
cancer patients in a training set with 89.3% SN and 84.7% SP 
and with 77.8% SN and 75.4% SP in an independent validation 
set. Yee et al45 demonstrated that circulating protein biomark-
ers connective tissue-activating peptide III/neutrophil activat-
ing protein-2 when combined with haptoglobin in a model that 
included age, smoking status, and forced expiratory volume 
in 1 second yielded an area under the curve (receiver oper-
ating characteristic) of 0.84, illustrating the value of includ-
ing clinical and demographic variables in diagnostic and risk 
TABLE 6. Predictions Made in Lung Cancer Cases with Small (3.5 cm) Pulmonary Masses Found on CT
 
Study No.
 
Referral Reason
Size of CT 
Mass (cm)a
Time to Diagnosis 
(Days)b
 
Staging
 
Predictionc
<3.5 cm
  37 Cough 3.2 13 IIA Cancer
  46 Sclerosis 1.6 8 IIIA Control
  52 F/Up for lipoma 1.3 96 IA Cancer
  88 Incidental 3.1 42 IIIa Cancer
  97 Pneumonia 2.1 5 IIIA Cancer
 107 Cough <0.5 (2) 80 Limitedd Cancer
 126 PluSS 1.6 5 IIIA Control
 189 Incidental 1.6 62 Ie Cancer
 273 Incidental 2.4 5 Ie Cancer
 297 Cough 1.3 43 IIIA Control
 327 Incidental 3.0 1 IIIe Control
 335 Incidental 2.7 50 IIIA Control
 358 PluSS 2.3 36 IIB Cancer
 364 PluSS 1.6 14 IA Cancer
 380 Dyspnea 2.8 62 Ie Cancer
 390 CoPD exacerbation 2.5 42 Ie Cancer
 410 PluSS 1.5 90 IA Cancer
 424 Dyspnea 2.0 37 Ie Cancer
 469 Incidental 1.6 33 Ie Cancer
 471 Dyspnea 2.7 49 Limitedd Cancer
>3.5 cm
  23 Cough 10 40 IIB Cancer
  31 Flank Pain 3.7 10 IB Cancer
  62 Hemoptysis 3.7 7 IB Control
 245 Incidental 10 3 IB Cancer
 311 Hemoptysis 4 1 IB Cancer
 370 Cough 4.2 110 Ie Control
 388 Shoulder pain 3.6 30 IB Control
 403 Chest pain 6 7 IV Cancer
 412 Incidental 3.5 71 IA Cancer
 483 Cough 3.0f 15 Extensived Cancer
aDiameter of CT mass finding that triggered invasive diagnostic procedure.
bTime interval between suspicious CT finding and biopsy-proven diagnosis.
cCase-control classification prediction from 10-biomarker panel model.
dSmall cell lung carcinoma only.
eClinical staging; patient deemed inoperable.
fWith enlarged lymph nodes.
CT, computed tomography; PluSS, Pittsburgh Lung Screening Study; CoPD, chronic obstructive pulmonary disease.
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prediction models for lung cancer. Patel et al46 published a six-
analyte serum test for NSCLC that included Cyfra 21.1 and 
E-selectin, two additional biomarkers included in our 10-bio-
marker panel, with observed high specificity against high-risk 
subjects without lung cancer except for individuals with lung 
nodules. Pine et al47 reported elevated levels of CRP, IL-6, and 
IL-8 in lung cancer patients in the National Cancer Institute-
Maryland study and demonstrated that elevated levels of serum 
IL-8 and CRP together were a better prediction classifier for 
lung cancer diagnosis than either marker considered alone. 
These associations with serum IL-6 and IL-8 levels appeared to 
be robust, being independent of smoking, age, sex, lung tumor 
histology, stage, presence or absence of systemic inflamma-
tion, and whether the lung cancers were clinically ascertained 
or diagnosed as a result of CT screening. Most recently, can-
didate biomarkers and panels of these biomarkers have been 
suggested from a study of four mouse models of human lung 
cancer by Taguchi et al.48 Also, of potential complementary 
diagnostic utility to circulating protein biomarkers, the analy-
sis of lung cancer serum autoantibodies has also been reported 
by Qiu et al49 and Wu et al.50 Combinations of these autoan-
tibody panels yield an area under the curve receiver operator 
characteristic performance similar to our results and previously 
published protein biomarker panels.
The performance of a cancer biomarker in screening the 
general population must be at an extremely high stringency, 
on the order of 99.5% accuracy. In contrast, in a clinical con-
text using a high-risk population, significant improvement 
in clinical workup for a specific disease could be achieved 
with tests that discriminate with substantially lower accuracy. 
Toward this goal of clinical application, we developed a highly 
performing 10-biomarker panel in a two-stage process by first 
identifying eight biomarkers that could discriminate NSCLC 
patients from those of matched tobacco-exposed controls in 
a training set and demonstrating its performance in a test set. 
We then combined all the data from the training and test sets 
to train a new model. Not surprisingly, the original eight bio-
markers remained in the model, but two additional markers 
were identified that showed considerable SP (93.3%) with 
minimal loss of SN (73.3%) in the blinded verification set, and 
showed ability to correctly classify lung cancers of divergent 
histologic subtypes. Training on a larger diverse set of cases 
and controls appears to have produced a more discriminatory 
model, despite the fact that the larger training set contained 
unmatched individuals.
In the blinded study which constituted an independent 
test set for the new model, the 10-biomarker panel operated 
at a BACC of 83.3% in all cases and CT-screened controls 
and 89.2% in stage I/II lung cancers and CT-screened controls, 
those tumors which are most likely to be identified on serial 
CT screens. Confounding by airflow obstruction and emphy-
sema appears to be minimal in this panel, based on similar 
misclassification rates in individuals with and without airway 
disease. Interestingly, although the model was developed by 
training only on lung adenocarcinomas and squamous cell 
carcinomas, in the blinded study the panel showed ability to 
correctly classify small cell carcinoma, and undifferentiated 
NSCLC, and also classified one of two pleomorphic carcino-
mas correctly. The biomarker panel will need to be formally 
validated in larger studies that would include examining sera 
from a wide range of lung cancer histologies, from patients 
who were diagnosed with lung cancer as the result of a screen-
ing CT nodule, and a larger group of CT-screened controls. 
The validation should also include subjects from another insti-
tution and a study of the temporal stability of these protein 
analytes in serum and the lead time found in their association 
with lung cancer.
CT screening detection of an indeterminate pulmonary 
nodule, a nonspecific but frequent finding in high-risk subjects 
with a smoking history, creates a diagnostic dilemma. This 
diagnostic challenge was highlighted in the recent publication 
of the NLST9 results in which high-risk subjects, defined for 
this trial as individuals between 55 and 74 years of age with a 
30 pack-year smoking history and, if a former smoker, having 
quit within the previous 15 years, were screened using low-
dose CT three times at 1-year intervals, resulting in 24.2% of 
the tests classified as positive by virtue of any size nodule or 
nodules of 4 mm or greater being detected. The vast majority 
(96.4%) of these screening findings were false positives for 
lung cancer, reflecting the poor specificity of present CT imag-
ing techniques. The smaller the nodule, the less the likelihood 
that it is malignant, and most of these nodules are classified 
as low suspicion upon follow-up and are not considered for 
biopsy or surgery. In our clinical experience, approximately 
20% of the 1- to 2-cm nodules that are concerning enough 
to be considered for biopsy are actually malignant. Given the 
substantial risks of invasive diagnostic thoracic procedures, 
unselective biopsy of every person with a small nodule is 
clinically unacceptable. Most CT screening protocols delay 
lung biopsy until a small nodule appears to grow when moni-
tored with repeated CT scans over time. At a population level, 
maximum benefit from early lung cancer detection through 
CT screening requires prompt diagnosis and treatment for 
individuals with cancer, while limiting the frequency of radio-
graphic follow-up and unnecessary lung biopsy for persons 
without cancer. In principle, immediate intervention for a 
small nodule could be restricted to individuals with validated 
risk factors. Risk factors we have used to construct a model 
in the PLuSS cohort include advanced age, cigarette smoking 
history, family history of lung cancer, severe airflow obstruc-
tion, and severe emphysema.13 However, the ability of this risk 
model to predict lung cancer in the PLuSS cohort operates 
with only 50% SP at 80% SN. That is, of every 100 individu-
als with 1- to 2-cm suspicious nodules, our predictive model, 
operating at 80% SN, theoretically would identify 16 of the 20 
persons for immediate biopsy who actually have lung cancer 
in this group. However, in a setting where only one of five 
subjects with a solitary nodule greater than 1 cm but lesser 
than 2 cm truly has lung cancer, an additional 40 individuals 
out of the 100 with 1- to 2-cm suspicious nodules would be 
incorrectly classified as needing an immediate biopsy because 
the model operates at only 50% SP.
To improve interpretation of CT images in the setting 
of a suspicious pulmonary nodule, the SN and SP needed is 
approximately 80% and 85 to 90% respectively, similar to the 
observed performance of the 10-biomarker panel for classify-
ing stage I/II cancer in our blinded study. Under these condi-
tions of classification performance, of the same 100 individuals 
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with suspicious nodules, 16 of 24 persons (67%) selected for 
immediate biopsy would be expected to have lung cancer and 
only 8 would be biopsied needlessly. Such a strategy could 
reduce the number of futile invasive procedures by 80% (40 
of 80 without lung cancer versus 8 of 80 without lung cancer). 
Although the biomarker model we described could not detect 
every lung cancer, it offers a significant clinical improvement 
over CT imaging alone. It remains to be proven in a valida-
tion study that patients with lung cancer who are identified by 
small pulmonary nodules can be correctly classified by our 
model. However, even an SN of 75% for this group would be 
an improvement over CT alone. Also, patients with nodules not 
identified as cancer by the model would continue to receive 
follow-up clinical monitoring and would be biopsied if the 
nodules grew in size, which is the current standard of care.
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